舒芬太尼后处理对犬心肌缺血/再灌注Bcl-2、Bax的影响及其与JAK2-STAT3信号通路的关系

目的 研究舒芬太尼后处理对心肌缺血/再灌注损伤(ischemiia/reperfusion injury,I/RI)细胞凋亡的影响以及与信号通路JAK2-STAT3的关系.方法 健康杂种家犬24只,体重10 kg～15 kg,按随机数字表法分为4组(每组6只):假手术组(Sham组,只穿线,不结扎),心肌缺血/再灌注(ischemia/reperfusion,I/R)组,舒芬太尼后处理组(SPO组,于再灌注前5min静脉注射舒芬太尼0.6 μg/kg),舒芬太尼后处理+AG490组(SPO+AG490组,于再灌注前5 min静脉注射l mg/kg AG490,特异性的JAK2抑制剂),除Sham组外,所有犬心脏都经历30 min缺血和120 min再灌注.再灌注120 min时,取各组缺血区心肌组织,采用末端脱氧核苷酸转移酶介导的dUTP原位切口末端标记(terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling,TUNEL)法测定心肌细胞的凋亡情况,免疫组化法测定各组Bcl-2、Bax以及磷酸化STAT3 (p-ATAT3)蛋白的表达,并计算Bcl-2和Bax表达的比值(Bcl-2/Bax).结果 再灌注120 min时,可在I/R组缺血区心肌组织中检测到大量凋亡心肌细胞(63.9±4.0)％,而舒芬太尼后处理显著降低心肌细胞凋亡指数(30.7±1.5)％;与Sham组比较,I/R组、SPO组和SPO+AG490组Bcl-2与Bax表达上调,I/R组Bcl-2/Bax比值降低,SPO组Bcl-2/Bax比值升高;舒芬太尼后处理使p-STAT3表达明显增加,特异性的阻断剂AG490抑制了舒芬太尼后处理对心肌I/RI凋亡的作用,即抑制p-STAT3表达的增加. 结论 舒芬太尼后处理对心肌I/RI细胞凋亡有一定的抑制作用,通过激活JAK2-STAT3信号转导通路上调Bcl-2蛋白和下调Bax蛋白来发挥作用.     

舒芬太尼后处理对大鼠心肌缺血再灌注时细胞凋亡的影响

目的 探讨舒芬太尼后处理对大鼠缺血再灌注时心肌细胞凋亡的影响.方法 健康雄性SD大鼠36只,体重250 ～ 280 g,采用随机数字表法,将大鼠随机分为3组(n=12):假手术组(S组)、缺血再灌注组(I/R组)和舒芬太尼后处理组(SP组).采用结扎左冠状动脉30 min,再灌注120min的方法制备心肌缺血再灌注模型.S组只挂线不结扎左冠状动脉;SP组于再灌注即刻静脉注射舒芬太尼3.0 μg/kg.于缺血再灌注期间记录HR和MAP.于再灌注120 min时,处死大鼠,取心脏,测定心肌梗死面积,采用RT-PCR测定心肌Bax mRNA和Bcl-2 mRNA的表达,采用TUNEL法检测心肌凋亡细胞,计算凋亡指数.结果 三大鼠各时点HR比较差异无统计学意义(P＞0.05);与S组比较,I/R组心肌缺血再灌注期间MAP降低(P＜0.05),SP组差异无统计学意义(P＞0.05),I/R组和SP组凋亡指数和Bax mRNA表达水平升高,I/R组Bcl-2 mRNA表达水平降低,SP组Bcl-2 mRNA表达水平升高(P＜0.05);与I/R组比较,SP组心肌梗死面积、凋亡指数和Bax mRNA表达水平降低,Bcl-2 n.RNA表达水平升高(P＜0.05).结论 舒芬太尼后处理可能通过上调Bcl-2表达,下调Bax表达,抑制细胞凋亡,从而减轻大鼠心肌缺血再灌注损伤.     

瑞芬太尼对大鼠肠缺血再灌注时肝细胞凋亡的影响

目的 评价瑞芬太尼对大鼠肠缺血再灌注时肝细胞凋亡的影响.方法 成年Wistar大鼠54只,随机分为3组(n=18):假手术组(S组)、肠缺血再灌注组(IIR组)和瑞芬太尼组(R组).IIR组及R组采用夹闭肠系膜上动脉1 h后再灌注的方法制备肠缺血再灌注模型,R组于缺血前10min开始静脉输注瑞芬太尼1 μg·kg-1·min-1至再灌注末,S组及IIR组给予等容量生理盐水.分别于再灌注1、3、6 h时处死6只大鼠,取肝组织,检测肝组织Bcl-2与Bax表达水平及肝细胞凋亡情况,计算肝细胞凋亡指数(AI).结果 与S组相比,IIR组和R组Bcl-2与Box表达上调,肝细胞AI升高,IIR组Bcl-2/Bax比值降低,R组Bcl-2/Bax比值升高(P<0.05);与IIR组相比,R组Bcl-2表达、Bcl-2/Bax比值升高,Box表达下调,肝细胞AI降低(P<0.05).结论 瑞芬太尼可抑制大鼠肠缺血再灌注时肝细胞凋亡,其机制与上调Bcl-2表达及抑制Bax表达上调有关.     

瑞芬太尼对大鼠肾缺血再灌注时细胞凋亡的影响

目的 评价瑞芬太尼对大鼠肾缺血再灌注时细胞凋亡的影响.方法 健康成年雄性SD大鼠75只,体重220～ 250 g,采用随机数字表法,将其分为3组(n=25)∶假手术组(S组)、肾缺血再灌注组(I/R组)和瑞芬太尼组(R组).I/R组和R组采用夹闭双侧肾动脉45 min时恢复灌注法建立肾缺血再灌注损伤模型.R组于缺血前15 min至再灌注30 min经尾静脉输注瑞芬太尼1.0μg· kg-1·min-1,S组和I/R组给予等容量生理盐水.于缺血前15 min(T0)、再灌注3 h(T1)、6 h(T2)、12h(T3)及24 h(T4)时取肾组织标本.采用流式细胞术检测肾细胞凋亡率及Bax、Bcl-2蛋白表达,采用RT-PCR检测Bax和Bcl-2的mRNA表达,计算Bcl-2/Bax蛋白及mRNA表达比值,采用Paller法行肾小管损伤评分.结果 与S组比较,I/R组和R组T1-4时肾小管损伤评分和肾细胞凋亡率升高,Bcl-2/Bax蛋白及mRNA表达比值T12时升高,T3,4时降低(P＜0.01);与I/R组比较,R组T1-4时肾小管损伤评分和肾细胞凋亡率降低,Bcl-2/Bax蛋白及mRNA表达比值升高(P＜0.05或0.01);与T0时比较,I/R组和R组T1-4时肾小管损伤评分和肾细胞凋亡率升高,Bcl-2/Bax蛋白及mRNA表达比值T1,2时升高,T3,4时降低(P＜0.01).结论 瑞芬太尼减轻大鼠肾缺血再灌注损伤的机制与其调节Bcl-2/Bax蛋白表达,抑制肾组织细胞凋亡有关.     

不同阿片受体在舒芬太尼后处理减轻大鼠心肌缺血再灌注损伤中的作用

目的 探讨不同阿片受体在舒芬太尼后处理减轻大鼠心肌缺血再灌注损伤中的作用.方法 健康雄性SD大鼠50只,4～6月龄,体重200 ～ 330 g,采用随机数字表法,将其分为9组,缺血再灌注组(I/R组,n=7)采用结扎左冠状动脉前降支(LAD)30 min、再灌注120 min的方法制备大鼠心肌缺血再灌注损伤模型;缺血后处理组(IPC组,n=7)再灌注前行缺血后处理,进行3个循环的10 s开放LAD 10 s阻断LAD;舒芬太尼后处理组(SP组,n=6)于再灌注前5 min静脉注射舒芬太尼1μg/kg行舒芬太尼后处理;κ受体拮抗剂nor-binaltorphimne+舒芬太尼后处理组(BNI+ SP组,n=5)、δ受体拮抗剂纳曲吲哚+舒芬太尼后处理组(NTD+ SP组,n=5)和μ受体拮抗剂CTOP+舒芬太尼后处理组(CTOP+ SP组,n=5)于舒芬太尼后处理前分别静脉注射BNI 5 mg/kg、纳曲吲哚5 mg/kg和CTOP 1 mg/kg;BNI组、NTD组和CTOP组分别于再灌注前5 min时静脉注射相应剂量BNI、纳曲吲哚和CTOP.于再灌注120 min时采集颈总动脉血样,测定血浆cTnI浓度,处死大鼠后,取心脏,确定心肌梗死(IS)与缺血危险区(AAR)体积的比值(IS/AAR值).结果 与I/R组比较,IPC组、SP组、BNI+ SP组和NTD+ SP组血浆cTnI浓度和IS/AAR值降低(P＜0.05),CTOP+ SP组、NTD组、BNI组和CTOP组血浆cTnI浓度和IS/AAR值差异无统计学意义(P＞0.05);与SP组比较,BNI+ SP组和NTD+ SP组IS/AAR值升高,CTOP+ SP组血浆cTnI浓度和IS/AAR值升高(P＜0.05).结论 μκ和δ阿片受体均介导了舒芬太尼后处理减轻大鼠心肌缺血再灌注损伤.     

δ、κ阿片受体对舒芬太尼预处理大鼠心肌缝隙连接蛋白43的影响

目的观察δ、κ阿片受体对舒芬太尼预处理大鼠心肌缝隙连接蛋白43(Cx43)的影响,探讨舒芬太尼抗缺血性心律失常的机制。方法健康雄性SD大鼠30只,2~3个月月龄,体重250~330g。采用随机数字表法将大鼠分为五组:对照组(C组),缺血-再灌注组(IR组),舒芬太尼预处理组(S组),δ受体拮抗剂纳曲吲哚+舒芬太尼预处理组(NS组),以及κ受体拮抗剂nor-BNI+舒芬太尼预处理组(BS组)。C组不结扎;IR组采用结扎左冠状动脉30min,再灌注120min的方法建立心肌缺血-再灌注损伤模型;S组在心肌缺血前给予舒芬太尼3μg/kg输注5min,停止5min,重复3次进行预处理;NS组和BS组分别于给舒芬太尼前10min和15min静脉注射纳曲吲哚和nor-BNI 5mg/kg。记录心电图并对缺血30min和再灌注30min进行心律失常评分。于心肌缺血-再灌注末处死大鼠,留取左心室心肌组织,行免疫组化染色法检测Cx43蛋白的表达;行RT-PCR技术检测大鼠心肌组织中Cx43 mRNA的表达。结果IR组、NS组和BS组心律失常评分明显高于C组(P0.05);S组和NS组心律失常评分明显低于IR组(P0.05);BS组心律失常评分明显高于S组(P0.05)。IR组、S组、NS组和BS组Cx43表达均明显低于C组(P0.05);S组Cx43表达明显高于IR组(P0.05);NS组和BS组Cx43表达明显低于S组(P0.05)。结论δ和κ阿片受体可能参与了舒芬太尼预处理上调心肌Cx43表达的过程,且κ阿片受体在抗缺血性心律失常中起到主导作用。     

异丙酚对大鼠小肠缺血再灌注时粘膜上皮细胞凋亡的影响

目的 探讨异丙酚对大鼠小肠缺血再灌注时粘膜上皮细胞凋亡的影响及其机制.方法 健康Wistar大鼠24只,随机分为3组(n=8):假手术组(S组)、缺血再灌注组(I/R组)和异丙酚+缺血再灌注组(P+I/R组).夹闭肠系膜上动脉,缺血1 h,再灌注2 h,制备小肠缺血再灌注损伤模型.S组和I/R组缺血前10 min开始经股静脉持续输注生理盐水10 ml·kg-1·h-1,P+I/R组静脉注射异丙酚10 mg/kg,以后持续输注异丙酚10 mg·kg-1·h-1.取空肠组织3 cm,常规制备全层石蜡切片,行HE染色,光镜下观察小肠组织病理学;免疫组化法检测Bcl-2、Bax蛋白的表达;TUNEL法检测小肠粘膜上皮细胞凋亡,计数凋亡细胞及总细胞,计算小肠粘膜上皮细胞凋亡指数.结果 与S组比较,I/R组和P+I/R组Bcl-2和Bax蛋白表达上调,Bcl-2/Bax增加,小肠组织损伤程度增强,小肠粘膜上皮细胞凋亡指数增高(P＜0.01或0.05);与I/R组比较,P+I/R组Bcl-2蛋白表达上调,Bax蛋白表达下调,小肠组织损伤程度减轻,小肠粘膜上皮细胞凋亡指数降低(P＜0.01).结论 异丙酚可减轻大鼠小肠缺血再灌注损伤时粘膜上皮细胞凋亡,其机制与上调Bcl-2基因的表达和下调Bax基因的表达有关.     

PI3K/Akt 信号通路在舒芬太尼后处理减轻在体大鼠心肌缺血-再灌注损伤中的作用

目的探讨PI3K/Akt信号通路在舒芬太尼后处理减轻在体大鼠心肌缺血-再灌注损伤时细胞凋亡中的作用。方法取90只健康成年雄性SD大鼠,采用随机数字表法分为五组:假手术组(Sham组),只穿线不结扎;缺血-再灌注组(IR组),结扎左冠状动脉前降支造成心肌缺血30min,再灌注120 min;舒芬太尼后处理组(Sufen组),在灌注即刻,给予舒芬太尼1.0μg/kg输注3min,再灌注处理同IR组;舒芬太尼后处理~+LY294002(PI3K抑制剂)组(SL组),再灌注前10min给予LY294002 0.3mg/kg,并行舒芬太尼后处理;LY294002组(IL组),再灌注前10 min给予LY294002 0.3mg/kg,再灌注120min。在缺血前即刻(T_0)、缺血30min(T_1)、再灌注60min(T_2)和再灌注120min(T_3)时记录HR和MAP;再灌注末,测定心肌梗死面积(IS/AAR);再灌注15 min时,采用Western blot法测定心肌组织总的Akt和磷酸化的Akt蛋白含量;在再灌注末,用RT_-PCR检测Bax和Bcl-2mRNA的表达。结果五组大鼠组间组内HR差异无统计学意义;T_2、T_3时IR组、SL组和IL组MAP明显低于Sham组(P0.05);Sufen组IS/AAR明显低于IR、SL和IL组(P0.05);五组心肌总的Akt蛋白含量表达差异无统计学意义;与Sufen组比较,sham、IR、SL和IL组磷酸化的Akt表达明显下调(P0.05),IR组、SL和IL组Bax mRNA的表达明显升高,Bcl-2mRAN的表达明显降低(P0.05)。结论舒芬太尼后处理可减轻心肌缺血-再灌注损伤,可能与激活PI3K/Akt信号通路,降低Bax和增加Bcl-2蛋白表达而达到抑制心肌细胞的凋亡有关。     

舒芬太尼后处理和七氟醚后处理对大鼠离体心脏缺血再灌注损伤的影响

目的 评价舒芬太尼后处理和七氟醚后处理对大鼠离体心脏缺血再灌注损伤的影响.方法 雄性SD大鼠,体重230～250 g,成功制备Langendorff离体灌注模型的40个心脏随机分为4组(n=10):缺血再灌注组(Ⅰ组)、七氟醚后处理组(Ⅱ组)、舒芬太尼后处理组(Ⅲ组)和七氟醚联合舒芬太尼后处理组(Ⅳ组).采用K-H液平衡灌注(灌注压10 kPa)30 min,全心缺血40 min再灌注120 min.再灌注即刻时Ⅱ组、Ⅲ组和Ⅳ组进行药物后处理15 min:Ⅱ组K-H液中通入3.0%七氟醚,Ⅲ组K-H液中加入100 nmol/L舒芬太尼,Ⅳ组同时进行七氟醚后处理和舒芬太尼后处理.分别于平衡灌注末(基础状态)、再灌注15 min、30 min、60 min、90 min、120 min时记录左室收缩压(LVSP)、左室舒张末压(LVEDP)、左室发展压(LVDP)、左室内压上升最大速率(+dp/dtmax)、左室内压下降最大速率(-dp/dtmax)、心率(HR)和灌脉流量(CF).再灌注5 min时,收集冠脉流出液,测定肌酸激酶(CK)和乳酸脱氢酶(LDH)的活性.再灌注120 min时取心肌组织,测定心肌梗死体积、Bcl-2和Bax的表达水平,并计算Bcl-2和Bax表达的比值(Bcl-2/Bax).结果 与Ⅰ组比较,Ⅱ组、Ⅲ组和Ⅳ组LVSP、LVDP、+dp/dtmax、-dp/dtmax和CF升高,LVEDP和LDH、CK的活性降低,心肌梗死体积缩小,Bcl-2表达上调,Bax表达下调,Bcl-2/Bax升高(P＜0.05或0.01);Ⅱ组、Ⅲ组和Ⅳ组间上述指标差异无统计学意义(P＞0.05).结论 舒芬太尼后处理可减轻大鼠心肌缺血再灌注损伤,联合七氟醚后处理时心肌保护作用并未增加,其心肌保护的机制与上调Bcl-2表达、下调Bax表达从而抑制细胞凋亡有关.     

瑞芬太尼对肝硬化大鼠肝脏缺血再灌注损伤的影响

目的 探讨瑞芬太尼对肝硬化大鼠肝脏缺血再灌注损伤的影响.方法 成年健康雄性SD大鼠30只,体重260～300 g,采用随机数字表法,将其随机分为3组(n=10):肝硬化组(C组)、肝硬化+肝缺血再灌注组(I/R组)和瑞芬太尼组(R组).C组、I/R组和R组采用四因素综合法制备大鼠肝硬化模型,I/R组和R组在肝硬化模型制备成功后1周制备大鼠70％肝脏缺血再灌注模型,R组于缺血前10 min开始静脉输注瑞芬太尼1μg·kg-1·min-至再灌注结束.于再灌注4h时取静脉血样和肝组织,测定血清ALT和AST活性、肝细胞Bcl-2和Bax表达及肝细胞凋亡情况,计算细胞凋亡指数,光镜下观察肝组织病理学结果.结果 与C组比较,I/R组血清ALT和AST的活性升高,肝细胞Bcl-2表达下调,Bax表达上调,细胞凋亡指数升高(P＜0.05);与I/R组比较,R组血清ALT和AST的活性降低,肝细胞Bcl-2表达上调,Bax表达下调,细胞凋亡指数降低(P＜0.05).R组肝组织病理学损伤轻于I/R组.结论 瑞芬太尼可减轻肝硬化大鼠肝脏缺血再灌注损伤,其机制与平衡肝细胞Bcl-2与Bax表达而抑制肝细胞凋亡有关.     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

Comparison of University of Wisconsin and University of Pittsburgh solutions for heart transplantation

The effectiveness of University of Wisconsin (UW) and University of Pittsburgh (UP) solutions for the preservation of rat hearts was compared. Lewis rat hearts were preserved with UW (group A, n=45) or UP (group B, n=45) solution for 0 or 24 h and then transplanted heterotopically into the recipients' abdomen. Ten recipients in each group were observed to obtain 1-week graft survival rates. Tissue water content and tissue content of adenine nucleotides were measured 2 h after transplantation in six grafts from each group. Six hearts preserved for 0 h and seven hearts preserved for 24 h were taken from each group 24 h after grafting for histopathology. The 1-week graft survival rates of groups A24 and B24 were 60% and 10%, respectively. In the 24-h preserved grafts, adenosine triphosphate (ATP) and energy charge [(ATP+adenosine diphosphate/2)/(ATP+adenosine diphosphate+adenosine monophosphate)] of groups A and B were 0.972±0.165 and 0.200±0.123 mg/g wet tissue (P<0.05) and 74.4% and 61.1% (P<0.05), respectively. The tissue water content of group A24 was 71.7%, whereas that of group B24 was 74.1% (P<0.05). Histopathology revealed more severe muscle edema and necrosis and infiltration of polymorphonuclear cells in group B24 than in group A24. We conclude that UW solution is more appropriate for rat heart preservation than UP solution.     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Long-term follow-up of callotasis lengthening of the capitate after resection of the lunate for the treatment of stage III lunate necrosis

The callotasis lengthening technique was used to gradually lengthen the capitate after resection of the lunate in stage IIIa necrosis in 23 patients. Results of ten patients with a follow-up of at least 5 years showed rapid and sufficient callus formation in every patient regardless of age. The callotasis lengthening modification of the Graner II operation provides all advantages and avoids the major inconvenience of the traditional Graner II operation. There was no increased rate of disturbed fracture healing. Results of the DTPA-gadolinium MRI study did not show any significant impairment of vascularization within the region of the capitate bone. With the “intrinsic bone formation,” contrary to every other intercarpal arthrodesis at the wrist, there is no need for an additional bone graft.     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

Magnetic resonance imaging for the evaluation of rejection of a kindney allograft in the rat

Orthotopic DA (RT1^a) into Lewis (RT1¹) rat kidney allografts and control Lewis-into-Lewis grafts were assessed by magnetic resonance imaging (MRI) and perfusion measurement after intravenous injection of a superparamagnetic contrast agent. MRI anatomical scores (range 1–6) and perfusion rates were compared with graft histology (rank of rejection score 1–6). Not only acute rejection, but also chronic events were monitored after acute rejection was prevented by daily cyclosporine (Sandimmune) treatment during the first 2 weeks after transplantation. In acute allograft rejection (n=11), MRI scores reached the maximum value of 6 and perfusion rates were severely reduced within 5 days after transplantation; histology showed severe acute rejection (histologic score 5–6). In the chronic phase (100–130 days after transplantation), allografts (n=5) manifested rejection (in histology cellular rejection and vessel changes), accompanied by MRI scores of around 2–3 and reduced perfusion rates. Both in the acute and chronic phases, the MRI anatomical score correlated significantly with the histological score (Spearman rank correlation coefficient r _s 0.89, n=30, P<0.01), and perfusion rates correlated significantly with the MRI score or histological score (r _s values between-0.60 and -0.87, n=23, P<0.01). It is concluded that MRI represents an interesting tool for assessing the anatomical and hemodynamical status of a kidney allograft in the acute and chronic phases after transplantation.     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.     

Cost-effectiveness of three combinations of antiemetics in the prevention of postoperative nausea and vomiting

Background. This study compares the cost-effectiveness of threecombinations of antiemetics in the prevention of postoperativenausea and vomiting (PONV). Methods. We conducted a prospective, double-blind study. NinetyASA I–II females, 18–65 yr, undergoing general anaesthesiafor major gynaecological surgery, with standardized postoperativeanalgesia (intrathecal 0.2 mg plus i.v. PCA morphine), wererandomly assigned to receive: ondansetron 4 mg plus droperidol1.25 mg after induction and droperidol 1.25 mg 12 h later (Group1); dexamethasone 8 mg plus droperidol 1.25 mg after inductionand droperidol 1.25 mg 12 h later (Group 2); ondansetron 4 mgplus dexamethasone 8 mg after induction and placebo 12 h later(Group 3). A decision analysis tree was used to divide eachgroup into nine mutually exclusive subgroups, depending on theincidence of PONV, need for rescue therapy, side effects andtheir treatment. Direct cost and probabilities were calculatedfor each subgroup, then a cost-effectiveness analysis was conductedfrom the hospital point of view. Results. Groups 1 and 3 were more effective (80 and 70%) thanGroup 2 (40%, P=0.004) in preventing PONV but also more expensive.Compared with Group 2, the incremental cost per extra patientwithout PONV was €6.99 (95% CI, –1.26 to 36.57) forGroup 1 and €13.55 (95% CI, 0.89–132.90) for Group3. Conclusion. Ondansetron+droperidol is cheaper and at least aseffective as ondansetron+ dexamethasone, and it is more effectivethan dexamethasone+droperidol with a reasonable extra cost. Br J Anaesth 2003; 91: 589–92